Kevin D. Bunker - Jun 1, 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Operating Officer
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kevin D. Bunker
Stock symbol
ZNTL
Transactions as of
Jun 1, 2021
Transactions value $
-$455,442
Form type
4
Date filed
6/2/2021, 08:26 PM
Next filing
Jul 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$409K -7.57K -17.98% $54.00 34.5K Jun 1, 2021 See Footnote F1, F2
transaction ZNTL Common Stock Sale -$46.6K -849 -2.46% $54.86 33.7K Jun 1, 2021 See Footnote F1, F3
holding ZNTL Common Stock 1.02M Jun 1, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.54 to $54.47. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.59 to $55.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.